Benralizumab is a monoclonal antibody that specifically targets the interleukin-5 receptor (IL-5R) on eosinophils, a type of white blood cell involved in allergic responses and asthma. It is primarily used in the treatment of severe asthma with an eosinophilic phenotype and is administered via subcutaneous injection. Benralizumab works by depleting eosinophils through antibody-dependent cell-mediated cytotoxicity, thereby reducing inflammation and improving respiratory function. The molecular structure of benralizumab consists of humanized IgG1 kappa monoclonal antibody components, which contribute to its stability and efficacy. It has a relatively long half-life, allowing for less frequent dosing compared to some other biologics. Common side effects may include injection site reactions, headache, and potential risk of infections due to its immunomodulatory effects. Overall, benralizumab represents a targeted therapeutic approach in managing eosinophilic asthma, providing significant benefits for patients with this specific condition.

Benralizumab

1044511-01-4: Fasenra, Benralizumab, MEDI 563, BIW 8405, Immunoglobulin G1, anti-(human interleukin 5 receptor α-chain) (human-mouse monoclonal MEDI-563 heavy chain), disulfide with human-mouse monoclonal MEDI-563 κ-chain, dimer

Anti-CD125 monoclonal antibody; asthma treatment

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα).

CAS 1044511-01-4: Benralizumab

Benralizumab

Ref: 3D-CLA1249

Benralizumab

Ref: TM-T10497